Mental Health Today Show | Anxiety Coping Skills & Mental Wellness · John Cordray, LPC | Anxiety & Mental Wellness Expert

Ketamine Therapy for Treatment-Resistant Depression: Dr. Irfan Fauq

·30 min·2 clips
Ketamine was developed in the 60s as an anesthetic, and S-ketamine received FDA approval for treatment-resistant depression in 2019.
1. The Mental Health Today Show, running since 2016, covers ketamine therapy for treatment-resistant depression in a roughly 30-minute interview recorded around Sierra Tucson's program. 2. Host John Cordray is a therapist, and guest Dr. Irfan Fauq is a practicing psychiatrist and director of ketamine services at Sierra Tucson, where he has worked about five and a half years. 3. Fauq's central point is that ketamine, developed in the 1960s as an anesthetic, now offers a rapid-acting option for people who have failed two or more antidepressant trials. 4. He explains that ketamine is a 50-50 mix of two molecular forms, and that one form, S-ketamine, was FDA-approved in 2019 for treatment-resistant depression and for major depressive disorder with suicidality. 5. He says formal ketamine therapy has been linked to greater reductions in depression scores than placebo, with results sometimes seen "as early as after the first dose," few drug-drug interactions, and a well-tolerated side effect profile. 6. He describes psychological effects such as reduced external stimuli, heightened internal perception, a feeling of interconnectedness, and less obsession-based thinking, and he cautions that expectations can "outweigh the results" with novel treatments. 7. On abuse concerns, he notes that abuse often occurs alongside other substance use at higher and more frequent doses than in depression treatment, and he cites two recent clinical reviews that found no suggestion of misuse when ketamine was prescribed for depression. 8. At Sierra Tucson, a Tucson, Arizona residential center with stays of around 30 days, Spravato is delivered intranasally two to three times a week for up to six sessions, and intramuscular ketamine follows a similar schedule although it lacks a formal FDA indication for these conditions. 9. He contrasts a vial costing about $7 with outpatient charges of $500 per dose and courses costing thousands of dollars, and he says Sierra Tucson offers ketamine at no cost when the treatment team recommends it. 10. This episode suits people with long-running depression and the loved ones considering residential care.
Listen to the show on